Molecular Vision: Han, Mol Vis 2012; 18:1-9. Table 2

Table 2. The clinical character of the intravitreal bevacizumab (IVB) pretreated group and sham treat group were comparable.

Clinical character	IVB treated (n=12)	sham (n=12)	p value
Male (%) ‡	50.00%	41.67%	0.69
Age (Year)†	50.33±7.60	53.25±5.14	0.28
Duration of DR (Month)†	11.50±7.75	18.41±11.90	0.11
Duration of Diabetes (Year)†	11.92±6.02	17.17±3.86	0.02*
Vision (LogMAR) ‡	1.93±0.47	2.16±0.47	0.21

Gender, age, duration of diabetic retinopathy, and vision distribution of patients in the two groups had no significant difference. Duration of diabetes in the sham group was significantly longer (* p<0.05) than that of the IVB treat group. IVB=intravitreal becacizumab. All data are represented by mean±SD, except for those representing percent (%), † Student’s t-test, ‡: NonParametric test (Mann–Whitney test).